Last quarter (Q4 2023), NeuBase Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, NeuBase Therapeutics's net income was $―. See NeuBase Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Sep 22	Sep 21	Sep 20	Sep 19	Sep 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 7.85M	$ 33.32M	$ -26.57M	$ 17.07M	$ 25.51M	$ 9.08M
Operating Income	$ -7.85M	$ -33.32M	$ -26.57M	$ -17.07M	$ -25.51M	$ -9.08M
Net Non Operating Interest Income Expense	$ 291.34K	$ 124.51K	$ -19.78K	$ -7.69K	$ -128.95K	$ 74.47K
Other Income Expense	$ -20.98K	$ 582.62K	$ -1.18M	$ -307.53K	$ -492.89K	$ -4.23M
Pretax Income	$ -7.54M	$ -33.78M	$ -25.41M	$ -17.38M	$ -26.13M	$ -13.24M
Tax Provision	-	$ -6.78M	$ 7.92M	-	-	-
Earnings From Equity Interest Net Of Tax	-	$ -415.75K	$ -224.53K	-	-	-
Net Income Common Stockholders	$ -7.54M	$ -33.78M	$ -25.41M	$ -17.38M	$ -26.13M	$ -13.24M
Basic EPS	$ -2.16	$ -1.04	$ -18.60	$ -0.89	$ -3.26	$ -4.60
Diluted EPS	$ -2.16	$ -1.04	$ -18.60	$ -0.89	$ -3.26	$ -4.60
Basic Average Shares	$ 35.24M	$ 32.49M	$ 1.37M	$ 19.62M	$ 8.27M	$ 2.82M
Diluted Average Shares	$ 35.24M	$ 32.49M	$ 1.37M	$ 19.62M	$ 8.27M	$ 2.82M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 3.25M	$ -33.32M	$ -26.57M	$ 17.07M	$ 25.51M	$ 9.08M
Net Income From Continuing And Discontinued Operation	$ -7.54M	$ -33.78M	$ -25.41M	$ -17.38M	$ -26.13M	$ -13.24M
Normalized Income	$ -2.72M	-	-	$ -16.93M	$ -25.64M	$ -8.41M
Interest Expense	-	-	-	$ 7.69K	$ 128.95K	-
EBIT	$ -7.54M	$ -33.75M	$ -25.38M	$ -17.38M	$ -26.00M	$ -9.08M
EBITDA	$ -3.79M	$ -32.49M	$ -24.80M	$ -17.10M	$ -25.87M	$ -7.95M

Currency in USD

NeuBase Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing